25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALNY (Alnylam) Stock Analysis
Buy, Hold or Sell?

Let's analyze Alnylam together

I guess you are interested in Alnylam Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Alnylam’s Financial Insights
  • 📈 Technical Analysis (TA) – Alnylam’s Price Targets

I'm going to help you getting a better view of Alnylam Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Alnylam Pharmaceuticals Inc

I send you an email if I find something interesting about Alnylam Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Alnylam (30 sec.)










1.2. What can you expect buying and holding a share of Alnylam? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.91
Expected worth in 1 year
$3.85
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$1.94
Return On Investment
0.4%

For what price can you sell your share?

Current Price per Share
$461.24
Expected price per share
$310.22 - $484.21
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Alnylam (5 min.)




Live pricePrice per Share (EOD)
$461.24
Intrinsic Value Per Share
$-2.57 - $113.12
Total Value Per Share
$-0.66 - $115.03

2.2. Growth of Alnylam (5 min.)




Is Alnylam growing?

Current yearPrevious yearGrowGrow %
How rich?$250.5m-$152.2m$268.5m230.8%

How much money is Alnylam making?

Current yearPrevious yearGrowGrow %
Making money-$79.7m-$18.2m-$61.5m-77.1%
Net Profit Margin-13.7%-6.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Alnylam (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#210 / 853

Most Revenue
#29 / 853

Most Profit
#806 / 853

Most Efficient
#337 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Alnylam?

Welcome investor! Alnylam's management wants to use your money to grow the business. In return you get a share of Alnylam.

First you should know what it really means to hold a share of Alnylam. And how you can make/lose money.

Speculation

The Price per Share of Alnylam is $461.24. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alnylam.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alnylam, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.91. Based on the TTM, the Book Value Change Per Share is $0.48 per quarter. Based on the YOY, the Book Value Change Per Share is $0.77 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alnylam.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.51-0.1%-0.61-0.1%-0.140.0%-0.93-0.2%-1.27-0.3%-1.22-0.3%
Usd Book Value Change Per Share1.030.2%0.480.1%0.770.2%0.050.0%-0.44-0.1%-0.220.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.030.2%0.480.1%0.770.2%0.050.0%-0.44-0.1%-0.220.0%
Usd Price Per Share326.09-276.61-190.24-224.62-197.46-142.99-
Price to Earnings Ratio-161.23--122.00--137.98--96.16--66.69--43.60-
Price-to-Total Gains Ratio316.25-738.53-3,516.49-1,345.11-742.79-312.60-
Price to Book Ratio170.57-512.80--2,682.19--785.38--455.68--223.50-
Price-to-Total Gains Ratio316.25-738.53-3,516.49-1,345.11-742.79-312.60-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share461.24
Number of shares2
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.48-0.44
Usd Total Gains Per Share0.48-0.44
Gains per Quarter (2 shares)0.97-0.88
Gains per Year (2 shares)3.87-3.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104-60-4-14
208-20-7-18
301220-11-22
401560-14-26
5019100-18-30
6023140-21-34
7027180-25-38
8031220-28-42
9035260-32-46
10039300-35-50

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%2.085.00.02.3%
Book Value Change Per Share4.00.00.0100.0%7.05.00.058.3%7.013.00.035.0%12.028.00.030.0%26.061.00.029.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.087.00.0%
Total Gains per Share4.00.00.0100.0%7.05.00.058.3%7.013.00.035.0%12.028.00.030.0%26.061.00.029.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Alnylam Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.0310.484+113%0.773+33%0.047+2076%-0.438+143%-0.221+121%
Book Value Per Share--1.9120.888+115%-1.161+161%-0.659+134%1.868+2%6.053-68%
Current Ratio--2.8012.842-1%3.101-10%3.144-11%3.591-22%6.552-57%
Debt To Asset Ratio--0.9450.974-3%1.040-9%1.026-8%0.929+2%0.579+63%
Debt To Equity Ratio--17.22160.974-72%-+100%20.325-15%14.393+20%7.372+134%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--41285708110.00034809380387.500+19%23380334115.725+77%27926515045.242+48%24723566976.645+67%18545663930.573+123%
Eps---0.506-0.609+20%-0.140-72%-0.926+83%-1.268+151%-1.221+141%
Ev To Ebitda Ratio--548.079273.190+101%-33.106+106%68.709+698%30.131+1719%3.923+13870%
Ev To Sales Ratio--13.34114.322-7%10.292+30%15.133-12%19.569-32%124.273-89%
Free Cash Flow Per Share--1.064-0.099+109%0.607+75%-0.175+116%-0.606+157%-0.780+173%
Free Cash Flow To Equity Per Share--1.4740.342+331%1.051+40%0.413+257%0.344+329%0.256+475%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--113.121----------
Intrinsic Value_10Y_min---2.569----------
Intrinsic Value_1Y_max--1.045----------
Intrinsic Value_1Y_min---2.651----------
Intrinsic Value_3Y_max--10.983----------
Intrinsic Value_3Y_min---5.939----------
Intrinsic Value_5Y_max--30.375----------
Intrinsic Value_5Y_min---6.982----------
Market Cap60458877960.000+29%42743551110.00036258089887.500+18%24947891865.725+71%29447209545.242+45%25885733776.645+65%18743473105.573+128%
Net Profit Margin---0.086-0.137+59%-0.069-20%-0.366+327%-0.716+736%-6.556+7554%
Operating Margin--0.006-0.102+1716%-0.006+194%-0.296+4791%-0.599+9585%-6.766+107190%
Operating Ratio--1.0211.080-5%0.998+2%1.254-19%1.550-34%10.483-90%
Pb Ratio241.265+29%170.571512.800-67%-2682.185+1672%-785.384+560%-455.682+367%-223.503+231%
Pe Ratio-228.054-41%-161.231-122.003-24%-137.977-14%-96.156-40%-66.692-59%-43.595-73%
Price Per Share461.240+29%326.090276.613+18%190.240+71%224.623+45%197.465+65%142.985+128%
Price To Free Cash Flow Ratio108.398+29%76.63640.220+91%-26.337+134%-13.702+118%-21.321+128%-21.473+128%
Price To Total Gains Ratio447.327+29%316.253738.531-57%3516.486-91%1345.113-76%742.794-57%312.603+1%
Quick Ratio--3.9734.081-3%4.466-11%4.494-12%5.251-24%10.329-62%
Return On Assets---0.015-0.019+28%-0.005-67%-0.033+129%-0.047+226%-0.067+359%
Return On Equity---0.264-1.365+416%--100%-0.455+72%-0.462+75%-0.288+9%
Total Gains Per Share--1.0310.484+113%0.773+33%0.047+2076%-0.438+143%-0.221+121%
Usd Book Value--250591000.000116367000.000+115%-152212250.000+161%-86384416.667+134%244775550.000+2%793469750.000-68%
Usd Book Value Change Per Share--1.0310.484+113%0.773+33%0.047+2076%-0.438+143%-0.221+121%
Usd Book Value Per Share--1.9120.888+115%-1.161+161%-0.659+134%1.868+2%6.053-68%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--41285708110.00034809380387.500+19%23380334115.725+77%27926515045.242+48%24723566976.645+67%18545663930.573+123%
Usd Eps---0.506-0.609+20%-0.140-72%-0.926+83%-1.268+151%-1.221+141%
Usd Free Cash Flow--139437000.000-13022000.000+109%79717000.000+75%-22824833.333+116%-79372250.000+157%-102238875.000+173%
Usd Free Cash Flow Per Share--1.064-0.099+109%0.607+75%-0.175+116%-0.606+157%-0.780+173%
Usd Free Cash Flow To Equity Per Share--1.4740.342+331%1.051+40%0.413+257%0.344+329%0.256+475%
Usd Market Cap60458877960.000+29%42743551110.00036258089887.500+18%24947891865.725+71%29447209545.242+45%25885733776.645+65%18743473105.573+128%
Usd Price Per Share461.240+29%326.090276.613+18%190.240+71%224.623+45%197.465+65%142.985+128%
Usd Profit---66277000.000-79772250.000+20%-18235250.000-72%-121297333.333+83%-166148300.000+151%-160013100.000+141%
Usd Revenue--773689000.000615490750.000+26%586101500.000+32%503646166.667+54%380776650.000+103%206614375.000+274%
Usd Total Gains Per Share--1.0310.484+113%0.773+33%0.047+2076%-0.438+143%-0.221+121%
 EOD+5 -3MRQTTM+31 -6YOY+23 -143Y+30 -75Y+28 -910Y+26 -11

3.3 Fundamental Score

Let's check the fundamental score of Alnylam Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-228.054
Price to Book Ratio (EOD)Between0-1241.265
Net Profit Margin (MRQ)Greater than0-0.086
Operating Margin (MRQ)Greater than00.006
Quick Ratio (MRQ)Greater than13.973
Current Ratio (MRQ)Greater than12.801
Debt to Asset Ratio (MRQ)Less than10.945
Debt to Equity Ratio (MRQ)Less than117.221
Return on Equity (MRQ)Greater than0.15-0.264
Return on Assets (MRQ)Greater than0.05-0.015
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Alnylam Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.440
Ma 20Greater thanMa 50457.484
Ma 50Greater thanMa 100404.491
Ma 100Greater thanMa 200348.558
OpenGreater thanClose465.210
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-08-23 09:55:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Alnylam earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • A Net Profit Margin of -8.6% means that $-0.09 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is -8.6%. The company is making a loss. -1
  • The TTM is -13.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8.6%TTM-13.7%+5.1%
TTM-13.7%YOY-6.9%-6.8%
TTM-13.7%5Y-71.6%+58.0%
5Y-71.6%10Y-655.6%+584.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.6%-85.5%+76.9%
TTM-13.7%-171.0%+157.3%
YOY-6.9%-210.0%+203.1%
3Y-36.6%-289.9%+253.3%
5Y-71.6%-381.1%+309.5%
10Y-655.6%-520.3%-135.3%
4.3.1.2. Return on Assets

Shows how efficient Alnylam is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • -1.5% Return on Assets means that Alnylam generated $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is -1.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM-1.9%+0.4%
TTM-1.9%YOY-0.5%-1.4%
TTM-1.9%5Y-4.7%+2.9%
5Y-4.7%10Y-6.7%+1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.5%-11.9%+10.4%
TTM-1.9%-11.9%+10.0%
YOY-0.5%-11.2%+10.7%
3Y-3.3%-12.0%+8.7%
5Y-4.7%-11.7%+7.0%
10Y-6.7%-13.8%+7.1%
4.3.1.3. Return on Equity

Shows how efficient Alnylam is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • -26.4% Return on Equity means Alnylam generated $-0.26 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is -26.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -136.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-26.4%TTM-136.5%+110.0%
TTM-136.5%YOY--136.5%
TTM-136.5%5Y-46.2%-90.3%
5Y-46.2%10Y-28.8%-17.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.4%-14.2%-12.2%
TTM-136.5%-15.2%-121.3%
YOY--15.3%+15.3%
3Y-45.5%-16.9%-28.6%
5Y-46.2%-17.5%-28.7%
10Y-28.8%-19.6%-9.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Alnylam Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Alnylam is operating .

  • Measures how much profit Alnylam makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • An Operating Margin of 0.6% means the company generated $0.01  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 0.6%. The company is operating inefficient. -1
  • The TTM is -10.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ0.6%TTM-10.2%+10.8%
TTM-10.2%YOY-0.6%-9.6%
TTM-10.2%5Y-59.9%+49.7%
5Y-59.9%10Y-676.6%+616.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6%-154.1%+154.7%
TTM-10.2%-280.2%+270.0%
YOY-0.6%-268.7%+268.1%
3Y-29.6%-281.5%+251.9%
5Y-59.9%-350.8%+290.9%
10Y-676.6%-530.7%-145.9%
4.3.2.2. Operating Ratio

Measures how efficient Alnylam is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.02 means that the operating costs are $1.02 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 1.021. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.080. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.021TTM1.080-0.059
TTM1.080YOY0.998+0.082
TTM1.0805Y1.550-0.469
5Y1.55010Y10.483-8.933
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0211.952-0.931
TTM1.0802.974-1.894
YOY0.9983.047-2.049
3Y1.2543.835-2.581
5Y1.5504.924-3.374
10Y10.4836.864+3.619
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Alnylam Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Alnylam is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.80 means the company has $2.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 2.801. The company is able to pay all its short-term debts. +1
  • The TTM is 2.842. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.801TTM2.842-0.041
TTM2.842YOY3.101-0.260
TTM2.8425Y3.591-0.750
5Y3.59110Y6.552-2.961
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8013.480-0.679
TTM2.8423.790-0.948
YOY3.1014.104-1.003
3Y3.1444.609-1.465
5Y3.5915.764-2.173
10Y6.5526.154+0.398
4.4.3.2. Quick Ratio

Measures if Alnylam is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • A Quick Ratio of 3.97 means the company can pay off $3.97 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 3.973. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.081. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.973TTM4.081-0.107
TTM4.081YOY4.466-0.386
TTM4.0815Y5.251-1.171
5Y5.25110Y10.329-5.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9732.938+1.035
TTM4.0813.291+0.790
YOY4.4663.928+0.538
3Y4.4944.393+0.101
5Y5.2515.837-0.586
10Y10.3296.549+3.780
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Alnylam Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Alnylam assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alnylam to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.95 means that Alnylam assets are financed with 94.5% credit (debt) and the remaining percentage (100% - 94.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 0.945. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.974. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.945TTM0.974-0.028
TTM0.974YOY1.040-0.066
TTM0.9745Y0.929+0.045
5Y0.92910Y0.579+0.349
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9450.339+0.606
TTM0.9740.359+0.615
YOY1.0400.334+0.706
3Y1.0260.341+0.685
5Y0.9290.349+0.580
10Y0.5790.379+0.200
4.5.4.2. Debt to Equity Ratio

Measures if Alnylam is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alnylam to the Biotechnology industry mean.
  • A Debt to Equity ratio of 1,722.1% means that company has $17.22 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alnylam Pharmaceuticals Inc:

  • The MRQ is 17.221. The company is unable to pay all its debts with equity. -1
  • The TTM is 60.974. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ17.221TTM60.974-43.753
TTM60.974YOY-+60.974
TTM60.9745Y14.393+46.581
5Y14.39310Y7.372+7.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.2210.391+16.830
TTM60.9740.436+60.538
YOY-0.436-0.436
3Y20.3250.461+19.864
5Y14.3930.461+13.932
10Y7.3720.514+6.858
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alnylam generates.

  • Above 15 is considered overpriced but always compare Alnylam to the Biotechnology industry mean.
  • A PE ratio of -161.23 means the investor is paying $-161.23 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alnylam Pharmaceuticals Inc:

  • The EOD is -228.054. Based on the earnings, the company is expensive. -2
  • The MRQ is -161.231. Based on the earnings, the company is expensive. -2
  • The TTM is -122.003. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-228.054MRQ-161.231-66.823
MRQ-161.231TTM-122.003-39.228
TTM-122.003YOY-137.977+15.974
TTM-122.0035Y-66.692-55.311
5Y-66.69210Y-43.595-23.097
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-228.054-2.539-225.515
MRQ-161.231-2.361-158.870
TTM-122.003-2.657-119.346
YOY-137.977-3.749-134.228
3Y-96.156-3.883-92.273
5Y-66.692-6.353-60.339
10Y-43.595-7.102-36.493
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alnylam Pharmaceuticals Inc:

  • The EOD is 108.398. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 76.636. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 40.220. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD108.398MRQ76.636+31.762
MRQ76.636TTM40.220+36.416
TTM40.220YOY-26.337+66.557
TTM40.2205Y-21.321+61.541
5Y-21.32110Y-21.473+0.152
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD108.398-3.411+111.809
MRQ76.636-2.951+79.587
TTM40.220-3.614+43.834
YOY-26.337-4.421-21.916
3Y-13.702-5.258-8.444
5Y-21.321-8.587-12.734
10Y-21.473-9.639-11.834
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Alnylam is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 170.57 means the investor is paying $170.57 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alnylam Pharmaceuticals Inc:

  • The EOD is 241.265. Based on the equity, the company is expensive. -2
  • The MRQ is 170.571. Based on the equity, the company is expensive. -2
  • The TTM is 512.800. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD241.265MRQ170.571+70.694
MRQ170.571TTM512.800-342.229
TTM512.800YOY-2,682.185+3,194.985
TTM512.8005Y-455.682+968.481
5Y-455.68210Y-223.503-232.179
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD241.2652.206+239.059
MRQ170.5712.027+168.544
TTM512.8002.194+510.606
YOY-2,682.1852.425-2,684.610
3Y-785.3842.571-787.955
5Y-455.6823.805-459.487
10Y-223.5034.462-227.965
4.6.2. Total Gains per Share

2.4. Latest News of Alnylam Pharmaceuticals Inc

Does Alnylam Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Alnylam Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-09-15
18:04
Validea Detailed Fundamental Analysis - ALNYRead
2025-09-13
15:03
Will Positive HELIOS-B Data and $575 Million Offering Transform Alnylam’s (ALNY) RNAi Therapy Narrative?Read
2025-09-10
07:49
Alnylam prices $575M convertible senior notesRead
2025-09-10
05:33
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028Read
2025-09-10
05:16
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior NotesRead
2025-09-09
05:30
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028Read
2025-09-06
19:08
ALNY Quantitative Stock AnalysisRead
2025-09-04
17:00
RNAi Technology Market Size to Reach USD 6.63 Billion with 10.4% CAGR by 2033, Report by DataM IntelligenceRead
2025-08-18
22:04
Validea Detailed Fundamental Analysis - ALNYRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alnylam Pharmaceuticals Inc.

4.8.1. Institutions holding Alnylam Pharmaceuticals Inc

Institutions are holding 99.104% of the shares of Alnylam Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Capital World Investors12.82050.796616805007553840.3307
2025-03-31FMR Inc11.67990.263915309860182395713.5249
2025-06-30Vanguard Group Inc10.14440.0702132971392405341.8422
2025-03-31BlackRock Inc7.29280.05429559382-325875-3.2966
2025-06-30Capital Research Global Investors5.48650.46957191656369280.5161
2025-06-30Regeneron Pharmaceuticals Inc3.390797.5951444444500
2025-06-30T. Rowe Price Investment Management,Inc.3.26620.88164281279-136866-3.0978
2025-03-31State Street Corp2.56840.03753366583-56294-1.6446
2025-06-30Dodge & Cox2.43910.58583197096-154666-4.6145
2025-06-30T. Rowe Price Associates, Inc.2.39930.11623145006-360162-10.2752
2025-06-30Baillie Gifford & Co Limited.2.3130.73843031891-625716-17.1073
2025-03-31Geode Capital Management, LLC1.77210.049223228341160345.258
2025-03-31JPMorgan Chase & Co1.69280.04382218872-31188-1.3861
2025-06-30Wellington Management Company LLP1.58360.12292075752-535234-20.4993
2025-06-30NORGES BANK1.55070.08272032680-423402-17.2389
2025-06-30American Century Companies Inc1.36850.31781793846334111.8979
2025-03-31Orbis Allan Gray Ltd1.24732.525163492316212111.0077
2025-03-31Groupama Asset Management1.1750.24991540139116890.7648
2025-03-31Winslow Capital Management, LLC0.90571.2786118717816661116.3253
2025-03-31Bank of America Corp0.81220.02321064573646021154.3467
Total 75.9087106.302199500141+643287+0.6%

4.9.2. Funds holding Alnylam Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30American Funds Growth Fund of Amer A7.76711.03511018107500
2025-06-30Capital Group Growth Fnd of Amer Comp7.76711.03511018107500
2025-06-30Vanguard Total Stock Mkt Idx Inv3.20280.07134198142435881.0492
2025-06-30American Funds New Perspective A2.23330.6142292742800
2025-06-30Capital Group New Perspective Comp2.23330.6142292742800
2025-06-30Vanguard Mid Cap Index Institutional2.1950.48652877174355561.2513
2025-06-30American Funds AMCAP A1.83240.8437240192000
2025-06-30Capital Group AMCAP Composite1.83240.8437240192000
2025-06-30Dodge & Cox Stock I1.55490.56772038100-130000-5.996
2025-06-30Vanguard Institutional Extnd Mkt Idx Tr1.53330.57042009838-9345-0.4628
2025-06-30Fidelity Growth Compy Commingled Pl S1.48740.6824194965218210.0935
2025-06-30Capital Group Growth Composite1.28641.0721168620000
2025-06-30American Funds IS® Growth 11.28641.0721168620000
2025-06-30American Funds Fundamental Invs A1.22380.3436160415400
2025-06-30Capital Group Fundamental Invtrs Comp1.22380.3436160415400
2025-06-30Vanguard Health Care Inv1.22321.45371603352-503516-23.8988
2025-06-30T. Rowe Price US Mid-Cap Growth Equity1.21971.87631598800-44400-2.702
2025-06-30T. Rowe Price Mid-Cap Growth1.21971.87631598800-1200-0.075
2025-06-30American Funds New Economy A1.16941.2841532833-75047-4.6675
2025-06-30Capital Group New Economy Comp1.16941.2841532833-75047-4.6675
Total 44.660817.9758541078-757590-1.3%

5.3. Insider Transactions

Insiders are holding 3.796% of the shares of Alnylam Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-08-19Pushkal GargSELL1455458.41
2025-08-18Jeffrey V PoultonSELL2274453.27
2025-08-18Kevin Joseph FitzgeraldSELL1396453.27
2025-08-18Michael W BonneySELL11250450
2025-08-18Pushkal GargSELL1396453.27
2025-08-18Tolga TangulerSELL1396453.27
2025-08-18Yvonne GreenstreetSELL6979453.27
2025-08-14Dennis A AusielloSELL31448436.58
2025-06-02Yvonne GreenstreetSELL19297306
2025-05-30Yvonne GreenstreetSELL31640304.39
2025-02-18Kevin Joseph FitzgeraldSELL1440251.56
2025-02-18Pushkal GargSELL1548251.67
2025-02-14Jeffrey V PoultonSELL967255.17
2025-02-14Kevin Joseph FitzgeraldSELL663255.21
2025-02-14Pushkal GargSELL1561255.17
2025-02-14Yvonne GreenstreetSELL1213255.17
2025-01-27Pushkal GargSELL52592285
2025-01-23Phillip A. SharpSELL11250275
2024-12-12Pushkal GargSELL1752251
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets4,566,019
Total Liabilities4,315,428
Total Stockholder Equity250,591
 As reported
Total Liabilities 4,315,428
Total Stockholder Equity+ 250,591
Total Assets = 4,566,019

Assets

Total Assets4,566,019
Total Current Assets3,643,699
Long-term Assets922,320
Total Current Assets
Cash And Cash Equivalents 1,113,685
Short-term Investments 1,743,900
Net Receivables 567,112
Inventory 71,688
Other Current Assets 147,314
Total Current Assets  (as reported)3,643,699
Total Current Assets  (calculated)3,643,699
+/-0
Long-term Assets
Property Plant Equipment 692,192
Long-term Assets Other 125,765
Long-term Assets  (as reported)922,320
Long-term Assets  (calculated)817,957
+/- 104,363

Liabilities & Shareholders' Equity

Total Current Liabilities1,300,847
Long-term Liabilities3,014,581
Total Stockholder Equity250,591
Total Current Liabilities
Short-term Debt 46,097
Accounts payable 102,393
Other Current Liabilities 1,137,277
Total Current Liabilities  (as reported)1,300,847
Total Current Liabilities  (calculated)1,285,767
+/- 15,080
Long-term Liabilities
Long term Debt 1,026,522
Capital Lease Obligations 270,542
Long-term Liabilities Other 1,356,079
Long-term Liabilities  (as reported)3,014,581
Long-term Liabilities  (calculated)2,653,143
+/- 361,438
Total Stockholder Equity
Common Stock1,310
Retained Earnings -7,411,504
Accumulated Other Comprehensive Income -29,952
Other Stockholders Equity 7,690,737
Total Stockholder Equity (as reported)250,591
Total Stockholder Equity (calculated)250,591
+/-0
Other
Capital Stock1,310
Cash and Short Term Investments 2,857,585
Common Stock Shares Outstanding 129,676
Current Deferred Revenue15,080
Liabilities and Stockholders Equity 4,566,019
Net Debt 183,379
Net Invested Capital 1,277,113
Net Working Capital 2,342,852
Property Plant and Equipment Gross 692,192
Short Long Term Debt Total 1,297,064



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-31
> Total Assets 
16,111
0
0
0
35,183
39,339
68,473
62,545
66,107
59,067
50,862
43,248
98,348
153,687
147,114
144,527
240,006
227,340
219,658
505,091
493,791
486,256
580,046
580,181
554,676
554,529
518,653
495,668
481,385
463,406
440,180
412,606
393,265
369,052
340,828
310,223
281,917
340,295
318,477
322,352
287,520
471,578
462,558
447,503
420,530
1,080,297
1,032,659
986,357
1,079,595
1,628,790
1,530,771
1,436,144
1,386,510
1,316,949
1,382,162
1,312,910
1,262,810
1,133,926
1,434,283
1,358,281
1,994,730
1,923,139
1,789,389
1,675,654
1,574,802
2,013,999
2,716,411
2,541,622
2,395,134
2,279,624
3,374,367
3,307,283
3,407,061
3,255,269
3,509,429
3,472,313
3,643,304
3,433,545
3,330,417
3,535,255
3,546,359
3,391,940
3,402,396
3,839,073
3,829,880
3,824,386
4,009,634
4,205,039
4,239,983
4,213,811
4,566,019
4,566,0194,213,8114,239,9834,205,0394,009,6343,824,3863,829,8803,839,0733,402,3963,391,9403,546,3593,535,2553,330,4173,433,5453,643,3043,472,3133,509,4293,255,2693,407,0613,307,2833,374,3672,279,6242,395,1342,541,6222,716,4112,013,9991,574,8021,675,6541,789,3891,923,1391,994,7301,358,2811,434,2831,133,9261,262,8101,312,9101,382,1621,316,9491,386,5101,436,1441,530,7711,628,7901,079,595986,3571,032,6591,080,297420,530447,503462,558471,578287,520322,352318,477340,295281,917310,223340,828369,052393,265412,606440,180463,406481,385495,668518,653554,529554,676580,181580,046486,256493,791505,091219,658227,340240,006144,527147,114153,68798,34843,24850,86259,06766,10762,54568,47339,33935,18300016,111
   > Total Current Assets 
0
0
0
0
24,189
22,586
50,511
47,198
48,181
41,442
33,840
26,697
82,414
137,120
129,057
126,827
222,784
209,916
201,958
477,632
397,905
455,475
550,631
451,779
443,124
419,339
278,422
228,165
293,534
273,309
409,297
244,623
254,139
348,917
322,414
293,175
152,028
208,539
304,083
303,415
125,557
240,111
214,359
199,164
254,028
674,063
665,121
643,017
746,367
1,090,186
1,029,150
1,041,793
1,105,388
1,050,074
888,068
747,564
989,241
597,188
960,709
993,368
1,782,830
1,691,160
1,502,559
1,342,120
1,209,319
1,392,013
2,063,773
1,897,265
1,715,864
1,584,773
2,160,446
2,054,702
2,614,777
1,970,083
2,725,163
2,675,362
2,808,576
2,589,677
2,471,638
2,690,847
2,692,247
2,541,018
2,524,047
2,985,452
2,982,697
2,988,607
3,172,856
3,355,424
3,295,285
3,268,258
3,643,699
3,643,6993,268,2583,295,2853,355,4243,172,8562,988,6072,982,6972,985,4522,524,0472,541,0182,692,2472,690,8472,471,6382,589,6772,808,5762,675,3622,725,1631,970,0832,614,7772,054,7022,160,4461,584,7731,715,8641,897,2652,063,7731,392,0131,209,3191,342,1201,502,5591,691,1601,782,830993,368960,709597,188989,241747,564888,0681,050,0741,105,3881,041,7931,029,1501,090,186746,367643,017665,121674,063254,028199,164214,359240,111125,557303,415304,083208,539152,028293,175322,414348,917254,139244,623409,297273,309293,534228,165278,422419,339443,124451,779550,631455,475397,905477,632201,958209,916222,784126,827129,057137,12082,41426,69733,84041,44248,18147,19850,51122,58624,1890000
       Cash And Cash Equivalents 
15,477
0
0
0
23,193
21,612
31,891
14,544
20,272
12,215
9,165
7,178
15,757
56,804
35,645
35,516
127,955
66,662
84,464
200,547
105,157
196,281
247,536
196,737
191,792
227,268
147,870
98,087
137,468
114,947
66,182
46,881
74,599
90,590
67,110
74,336
70,228
61,739
48,274
75,838
51,405
97,804
24,975
11,840
53,169
350,589
80,727
82,721
75,179
306,580
151,262
149,218
180,895
231,278
271,076
168,481
193,617
171,079
408,671
202,045
645,361
396,149
361,457
316,608
420,146
724,959
1,136,289
923,304
547,178
467,779
580,829
496,704
496,580
379,543
745,767
1,093,991
819,975
534,081
575,558
1,073,228
866,394
672,245
657,800
1,033,024
812,688
681,879
968,492
1,099,920
966,428
1,019,654
1,113,685
1,113,6851,019,654966,4281,099,920968,492681,879812,6881,033,024657,800672,245866,3941,073,228575,558534,081819,9751,093,991745,767379,543496,580496,704580,829467,779547,178923,3041,136,289724,959420,146316,608361,457396,149645,361202,045408,671171,079193,617168,481271,076231,278180,895149,218151,262306,58075,17982,72180,727350,58953,16911,84024,97597,80451,40575,83848,27461,73970,22874,33667,11090,59074,59946,88166,182114,947137,46898,087147,870227,268191,792196,737247,536196,281105,157200,54784,46466,662127,95535,51635,64556,80415,7577,1789,16512,21520,27214,54431,89121,61223,19300015,477
       Short-term Investments 
19
0
0
0
373
0
14,207
30,393
25,774
26,075
22,477
17,631
64,245
75,471
87,622
84,758
89,305
137,804
110,304
267,831
284,791
247,592
290,787
223,379
238,596
180,786
119,368
119,883
143,934
146,811
193,012
184,486
158,532
154,050
150,839
98,685
76,174
137,356
180,750
152,498
71,407
138,207
184,719
181,939
192,701
314,901
574,035
549,213
621,512
760,293
853,368
866,992
899,636
782,356
585,326
544,655
433,182
388,525
514,600
746,249
1,045,257
1,171,715
1,086,209
920,226
664,009
519,578
790,542
797,754
988,984
874,424
1,344,735
1,337,172
1,377,815
1,329,994
1,154,315
1,233,874
1,615,589
1,705,482
1,535,055
1,192,101
1,326,012
1,398,430
1,399,707
1,373,254
1,626,694
1,689,403
1,656,157
1,680,315
1,728,076
1,612,568
1,743,900
1,743,9001,612,5681,728,0761,680,3151,656,1571,689,4031,626,6941,373,2541,399,7071,398,4301,326,0121,192,1011,535,0551,705,4821,615,5891,233,8741,154,3151,329,9941,377,8151,337,1721,344,735874,424988,984797,754790,542519,578664,009920,2261,086,2091,171,7151,045,257746,249514,600388,525433,182544,655585,326782,356899,636866,992853,368760,293621,512549,213574,035314,901192,701181,939184,719138,20771,407152,498180,750137,35676,17498,685150,839154,050158,532184,486193,012146,811143,934119,883119,368180,786238,596223,379290,787247,592284,791267,831110,304137,80489,30584,75887,62275,47164,24517,63122,47726,07525,77430,39314,207037300019
       Net Receivables 
0
0
0
0
0
0
3,000
916
1,169
2,164
960
587
755
3,116
3,591
4,847
3,829
4,393
5,615
5,129
5,031
9,680
5,126
24,140
4,188
5,831
5,857
5,022
6,044
4,505
6,358
4,881
14,119
1,150
1,308
2,027
1,468
2,192
4,385
1,918
104
558
460
609
4,248
164
89
384
39,937
10,107
9,403
8,130
8,298
8,814
9,514
15,146
23,334
19,457
15,405
14,644
34,002
50,768
2,961
3,362
18,760
33,801
30,739
48,109
43,011
75,572
69,115
79,118
602,413
110,626
646,587
141,064
198,571
156,533
142,271
184,513
237,963
219,434
220,635
325,445
327,787
321,377
309,481
353,852
405,308
418,035
567,112
567,112418,035405,308353,852309,481321,377327,787325,445220,635219,434237,963184,513142,271156,533198,571141,064646,587110,626602,41379,11869,11575,57243,01148,10930,73933,80118,7603,3622,96150,76834,00214,64415,40519,45723,33415,1469,5148,8148,2988,1309,40310,10739,937384891644,2486094605581041,9184,3852,1921,4682,0271,3081,15014,1194,8816,3584,5056,0445,0225,8575,8314,18824,1405,1269,6805,0315,1295,6154,3933,8294,8473,5913,1167555879602,1641,1699163,000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-253,173
0
0
-239,721
-212,872
-168,112
0
0
-222,091
-222,657
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,081
24,068
32,001
40,587
54,562
56,348
68,300
77,418
66,942
75,202
73,940
84,358
97,899
86,363
78,516
88,976
115,489
128,962
131,879
100,453
95,771
89,146
93,988
83,981
75,987
78,509
65,581
71,688
71,68865,58178,50975,98783,98193,98889,14695,771100,453131,879128,962115,48988,97678,51686,36397,89984,35873,94075,20266,94277,41868,30056,34854,56240,58732,00124,06811,08100000000000000000000000-222,657-222,09100-168,112-212,872-239,72100-253,173000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
10,994
16,753
17,962
15,347
17,926
17,625
17,022
16,551
15,934
16,567
18,057
17,700
17,222
17,424
17,700
27,459
95,886
30,781
29,415
128,402
111,552
135,190
240,231
267,503
187,851
190,097
30,883
167,983
139,126
20,135
18,414
17,048
129,889
131,756
14,394
18,937
161,963
231,467
248,199
248,339
166,502
406,234
367,538
343,340
333,228
538,604
501,621
394,351
281,122
266,875
494,094
565,346
273,569
536,738
473,574
364,913
211,900
231,979
286,830
333,534
365,483
621,986
652,638
644,357
679,270
694,851
1,213,921
1,252,581
792,284
1,285,186
784,266
796,951
834,728
843,868
858,779
844,408
854,112
850,922
878,349
853,621
847,183
835,779
836,778
849,615
944,698
945,553
922,320
922,320945,553944,698849,615836,778835,779847,183853,621878,349850,922854,112844,408858,779843,868834,728796,951784,2661,285,186792,2841,252,5811,213,921694,851679,270644,357652,638621,986365,483333,534286,830231,979211,900364,913473,574536,738273,569565,346494,094266,875281,122394,351501,621538,604333,228343,340367,538406,234166,502248,339248,199231,467161,96318,93714,394131,756129,88917,04818,41420,135139,126167,98330,883190,097187,851267,503240,231135,190111,552128,40229,41530,78195,88627,45917,70017,42417,22217,70018,05716,56715,93416,55117,02217,62517,92615,34717,96216,75310,9940000
       Property Plant Equipment 
526
0
0
0
4,756
8,961
11,436
8,969
11,694
11,540
11,084
10,760
10,580
11,359
13,044
12,856
12,173
12,527
12,965
10,434
13,810
15,875
18,853
19,577
19,194
19,321
18,483
18,152
18,324
18,304
18,554
18,399
18,289
17,021
16,252
15,309
14,643
13,703
14,206
18,792
19,799
18,983
18,045
16,974
16,448
15,731
16,953
18,806
21,740
21,166
25,169
26,316
27,812
36,814
55,394
74,219
114,572
129,962
147,533
161,899
181,900
201,979
227,839
272,652
320,658
568,124
598,126
619,900
646,376
651,094
668,800
689,924
706,514
701,785
708,789
720,794
733,633
733,158
732,122
733,623
738,630
738,081
736,275
729,076
725,789
718,928
715,462
703,405
693,932
695,917
692,192
692,192695,917693,932703,405715,462718,928725,789729,076736,275738,081738,630733,623732,122733,158733,633720,794708,789701,785706,514689,924668,800651,094646,376619,900598,126568,124320,658272,652227,839201,979181,900161,899147,533129,962114,57274,21955,39436,81427,81226,31625,16921,16621,74018,80616,95315,73116,44816,97418,04518,98319,79918,79214,20613,70314,64315,30916,25217,02118,28918,39918,55418,30418,32418,15218,48319,32119,19419,57718,85315,87513,81010,43412,96512,52712,17312,85613,04411,35910,58010,76011,08411,54011,6948,96911,4368,9614,756000526
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
138,907
140,523
120,389
100,917
99,881
114,639
114,971
117,822
63,741
67,482
142,164
212,484
230,154
231,365
150,054
390,503
350,585
324,534
279,821
483,771
456,798
358,629
251,839
228,590
287,229
339,566
324,799
255,305
174,570
51,543
13,919
648
0
0
0
44,825
44,825
14,825
14,825
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000014,82514,82544,82544,82500064813,91951,543174,570255,305324,799339,566287,229228,590251,839358,629456,798483,771279,821324,534350,585390,503150,054231,365230,154212,484142,16467,48263,741117,822114,971114,63999,881100,917120,389140,523138,907000000000000000000000000000000
       Intangible Assets 
0
0
0
0
3,878
3,760
3,642
3,523
3,405
3,287
3,168
3,050
2,491
2,387
2,284
2,180
1,933
1,835
1,737
1,610
968
925
882
838
795
751
708
665
622
578
535
491
448
405
361
318
275
231
188
145
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
697,784
0
0
0
0
0
0
000000697,784000000000000000000000000000000000000000000001451882312753183614054484915355786226657087517958388829259681,6101,7371,8351,9332,1802,2842,3872,4913,0503,1683,2873,4053,5233,6423,7603,8780000
       Long-term Assets Other 
0
0
0
0
2,360
4,032
2,884
2,855
2,827
2,798
2,770
2,741
2,863
2,821
2,729
2,664
3,116
3,062
2,998
15,415
6,325
13,981
9,680
107,987
3,152
3,152
0
0
0
155,572
0
0
120,389
100,917
99,881
114,639
564
117,822
63,741
67,482
101
0
0
0
0
0
0
0
311,488
483,771
456,798
358,629
1,471
1,471
151,471
151,561
150,000
151,471
151,471
151,471
34,171
35,215
14,166
60,882
53,448
9,037
9,687
9,632
18,069
43,757
545,121
562,657
85,770
583,401
75,477
76,157
101,095
110,710
126,657
110,785
115,482
112,841
142,074
124,545
111,293
116,851
121,316
146,210
133,903
142,412
125,765
125,765142,412133,903146,210121,316116,851111,293124,545142,074112,841115,482110,785126,657110,710101,09576,15775,477583,40185,770562,657545,12143,75718,0699,6329,6879,03753,44860,88214,16635,21534,171151,471151,471151,471150,000151,561151,4711,4711,471358,629456,798483,771311,488000000010167,48263,741117,822564114,63999,881100,917120,38900155,5720003,1523,152107,9879,68013,9816,32515,4152,9983,0623,1162,6642,7292,8212,8632,7412,7702,7982,8272,8552,8844,0322,3600000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,674
8,570
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,667
33,667
19,654
9,406
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000009,40619,65433,66731,66700000000000000008,5708,674000000000000000000000000000000
> Total Liabilities 
2,673
0
0
0
61,890
78,419
17,798
17,564
19,965
19,238
21,474
20,177
36,569
35,771
37,037
39,750
38,832
37,313
40,388
312,156
294,623
283,444
380,877
375,624
352,551
355,785
334,171
313,647
303,420
291,576
274,702
251,963
235,032
223,485
204,277
182,350
163,920
142,917
130,190
145,192
153,467
160,022
154,383
149,921
150,183
125,324
90,390
81,879
143,328
132,280
122,167
114,540
121,796
127,898
283,680
297,942
342,589
303,025
311,317
299,446
228,299
168,334
168,587
197,535
272,837
467,013
959,216
934,535
956,442
929,895
1,974,641
2,092,260
2,390,814
2,329,079
2,656,067
2,716,420
3,055,101
3,032,379
3,154,377
3,602,893
3,704,582
3,651,180
3,810,527
4,004,939
4,050,524
4,043,658
4,012,701
4,172,685
4,172,895
4,098,376
4,315,428
4,315,4284,098,3764,172,8954,172,6854,012,7014,043,6584,050,5244,004,9393,810,5273,651,1803,704,5823,602,8933,154,3773,032,3793,055,1012,716,4202,656,0672,329,0792,390,8142,092,2601,974,641929,895956,442934,535959,216467,013272,837197,535168,587168,334228,299299,446311,317303,025342,589297,942283,680127,898121,796114,540122,167132,280143,32881,87990,390125,324150,183149,921154,383160,022153,467145,192130,190142,917163,920182,350204,277223,485235,032251,963274,702291,576303,420313,647334,171355,785352,551375,624380,877283,444294,623312,15640,38837,31338,83239,75037,03735,77136,56920,17721,47419,23819,96517,56417,79878,41961,8900002,673
   > Total Current Liabilities 
2,673
0
0
0
3,844
8,193
8,704
6,640
6,575
6,138
9,021
8,002
18,484
19,990
20,601
21,530
22,925
23,498
27,106
87,456
83,478
84,910
105,727
102,024
99,452
104,251
102,331
101,121
110,733
98,571
271,153
99,433
102,046
219,060
19,329
17,716
80,990
66,638
19,747
20,007
48,345
49,750
53,066
54,895
53,864
83,831
53,745
56,849
95,334
80,693
66,598
57,112
62,099
66,369
70,575
81,761
192,589
95,786
108,726
101,045
198,299
138,334
113,659
121,503
242,837
149,163
328,604
352,864
352,594
338,791
384,302
480,241
585,270
494,825
554,648
610,656
695,710
605,963
657,685
772,791
767,915
673,391
788,639
949,785
967,786
941,709
1,055,251
1,220,663
1,186,272
1,075,623
1,300,847
1,300,8471,075,6231,186,2721,220,6631,055,251941,709967,786949,785788,639673,391767,915772,791657,685605,963695,710610,656554,648494,825585,270480,241384,302338,791352,594352,864328,604149,163242,837121,503113,659138,334198,299101,045108,72695,786192,58981,76170,57566,36962,09957,11266,59880,69395,33456,84953,74583,83153,86454,89553,06649,75048,34520,00719,74766,63880,99017,71619,329219,060102,04699,433271,15398,571110,733101,121102,331104,25199,452102,024105,72784,91083,47887,45627,10623,49822,92521,53020,60119,99018,4848,0029,0216,1386,5756,6408,7048,1933,8440002,673
       Short-term Debt 
0
0
0
0
558
0
0
379
790
1,288
1,776
1,765
1,876
2,006
2,721
3,046
3,217
3,295
3,617
3,705
2,408
3,888
3,968
3,227
6,111
1,033
1,829
1,057
5,644
8,656
7,991
237
0
12,534
81,205
76,211
0
0
23,089
19,837
4,248
7,315
5,232
2,023
2,925
28,113
8,178
5,858
5,011
7,025
5,313
0
6,732
7,577
0
0
11,498
150,000
150,000
150,000
10,973
15,275
30,000
0
62,885
16,977
29,347
28,165
27,688
29,043
33,447
32,192
36,872
38,917
39,362
40,612
40,548
41,290
41,236
41,581
41,967
43,055
42,074
41,516
41,510
41,672
41,656
42,144
41,886
46,011
46,097
46,09746,01141,88642,14441,65641,67241,51041,51642,07443,05541,96741,58141,23641,29040,54840,61239,36238,91736,87232,19233,44729,04327,68828,16529,34716,97762,885030,00015,27510,973150,000150,000150,00011,498007,5776,73205,3137,0255,0115,8588,17828,1132,9252,0235,2327,3154,24819,83723,0890076,21181,20512,53402377,9918,6565,6441,0571,8291,0336,1113,2273,9683,8882,4083,7053,6173,2953,2173,0462,7212,0061,8761,7651,7761,288790379005580000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
150,000
150,000
150,000
150,000
30,000
30,000
30,000
0
0
16,977
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000016,9770030,00030,00030,000150,000150,000150,000150,00000000000000000000000000000000000000000000000000000000000
       Accounts payable 
674
0
0
0
1,510
3,636
1,810
1,450
910
1,653
1,612
1,985
1,975
3,928
3,698
2,456
4,085
3,007
5,669
7,057
3,826
9,084
6,240
3,342
2,588
8,729
6,463
8,426
12,489
15,742
17,823
6,561
9,312
17,850
7,949
5,486
5,800
4,339
5,519
5,093
4,420
3,105
4,534
2,728
5,896
5,037
6,168
5,201
15,111
15,486
15,715
14,272
16,787
17,442
12,824
23,137
54,465
25,371
23,170
9,239
28,355
13,206
11,988
21,772
59,708
22,671
71,215
39,392
49,884
40,484
26,125
27,872
51,966
45,381
53,079
40,048
73,426
54,916
52,418
40,572
98,094
62,237
59,746
73,840
55,519
78,148
73,980
70,805
88,415
97,399
102,393
102,39397,39988,41570,80573,98078,14855,51973,84059,74662,23798,09440,57252,41854,91673,42640,04853,07945,38151,96627,87226,12540,48449,88439,39271,21522,67159,70821,77211,98813,20628,3559,23923,17025,37154,46523,13712,82417,44216,78714,27215,71515,48615,1115,2016,1685,0375,8962,7284,5343,1054,4205,0935,5194,3395,8005,4867,94917,8509,3126,56117,82315,74212,4898,4266,4638,7292,5883,3426,2409,0843,8267,0575,6693,0074,0852,4563,6983,9281,9751,9851,6121,6539101,4501,8103,6361,510000674
       Other Current Liabilities 
1,999
0
0
0
1,443
4,141
5,443
3,740
3,875
1,678
4,243
2,986
3,899
3,669
4,583
5,104
4,479
7,297
9,980
11,746
13,111
9,666
9,497
11,420
10,889
10,389
9,908
8,381
9,833
9,592
8,263
11,365
11,116
12,534
11,864
12,714
12,824
13,889
1,364
2,755
12,508
10,074
9,740
16,586
15,272
42,848
16,494
20,522
56,352
49,104
38,423
28,867
29,960
31,983
38,866
37,537
43,694
33,660
45,762
53,274
74,191
66,322
92,510
96,287
116,290
106,873
138,800
177,948
197,201
183,221
217,143
305,576
369,225
294,187
364,063
414,952
432,253
377,919
449,739
546,430
585,749
532,305
632,180
757,289
768,004
745,039
870,606
1,036,684
1,000,490
904,053
1,137,277
1,137,277904,0531,000,4901,036,684870,606745,039768,004757,289632,180532,305585,749546,430449,739377,919432,253414,952364,063294,187369,225305,576217,143183,221197,201177,948138,800106,873116,29096,28792,51066,32274,19153,27445,76233,66043,69437,53738,86631,98329,96028,86738,42349,10456,35220,52216,49442,84815,27216,5869,74010,07412,5082,7551,36413,88912,82412,71411,86412,53411,11611,3658,2639,5929,8338,3819,90810,38910,88911,4209,4979,66613,11111,7469,9807,2974,4795,1044,5833,6693,8992,9864,2431,6783,8753,7405,4434,1411,4430001,999
   > Long-term Liabilities 
0
0
0
0
58,046
70,226
9,094
10,924
13,390
13,100
12,453
12,175
18,085
15,781
16,436
18,220
15,907
13,815
13,282
224,700
211,145
198,534
275,150
273,600
253,099
251,534
231,840
212,526
192,687
193,005
3,549
152,530
132,986
4,425
184,948
164,634
82,930
76,279
110,443
125,185
105,122
110,272
101,317
95,026
96,319
41,493
36,645
25,030
47,994
51,587
55,569
57,428
59,697
61,529
213,105
216,181
150,000
207,239
202,591
198,401
30,000
30,000
54,928
76,032
30,000
317,850
630,612
581,671
603,848
591,104
1,590,339
1,612,019
1,805,544
1,834,254
2,101,419
2,105,764
2,359,391
2,426,416
2,496,692
2,830,102
2,936,667
2,977,789
3,021,888
3,055,154
3,082,738
3,101,949
2,957,450
2,952,022
2,986,623
3,022,753
3,014,581
3,014,5813,022,7532,986,6232,952,0222,957,4503,101,9493,082,7383,055,1543,021,8882,977,7892,936,6672,830,1022,496,6922,426,4162,359,3912,105,7642,101,4191,834,2541,805,5441,612,0191,590,339591,104603,848581,671630,612317,85030,00076,03254,92830,00030,000198,401202,591207,239150,000216,181213,10561,52959,69757,42855,56951,58747,99425,03036,64541,49396,31995,026101,317110,272105,122125,185110,44376,27982,930164,634184,9484,425132,986152,5303,549193,005192,687212,526231,840251,534253,099273,600275,150198,534211,145224,70013,28213,81515,90718,22016,43615,78118,08512,17512,45313,10013,39010,9249,09470,22658,0460000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
150,000
150,000
150,000
150,000
150,000
150,000
30,000
30,000
30,000
30,000
30,000
30,000
30,000
0
0
0
0
0
191,278
0
0
0
675,697
0
0
1,015,975
1,016,942
1,017,887
1,018,843
0
0
0
0
0
0
0
0
000000001,018,8431,017,8871,016,9421,015,97500675,697000191,2780000030,00030,00030,00030,00030,00030,00030,000150,000150,000150,000150,000150,000150,000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,674
8,570
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,667
33,667
19,654
9,406
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000009,40619,65433,66731,66700000000000000008,5708,674000000000000000000000000000000
       Other Liabilities 
0
0
0
0
1,556
1,472
3,389
4,333
6,979
6,622
6,266
6,393
12,566
10,461
10,102
11,783
9,988
8,750
8,376
220,754
209,569
196,579
274,212
272,881
252,853
251,534
231,840
212,526
192,493
193,005
172,669
152,530
132,986
124,141
103,743
88,423
82,930
76,279
73,126
90,434
105,122
110,272
101,317
95,026
96,319
41,493
36,645
25,030
47,994
51,587
55,569
57,428
59,697
61,529
63,105
66,181
60,890
57,239
52,591
48,401
54,048
22,951
24,928
46,032
63,343
5,550
323,401
305,215
327,713
315,322
1,308,721
1,314,757
1,423,842
1,354,649
1,379,709
1,385,935
1,402,347
1,472,318
1,546,953
1,547,804
406,371
415,303
451,183
476,820
0
0
0
0
0
0
0
0000000476,820451,183415,303406,3711,547,8041,546,9531,472,3181,402,3471,385,9351,379,7091,354,6491,423,8421,314,7571,308,721315,322327,713305,215323,4015,55063,34346,03224,92822,95154,04848,40152,59157,23960,89066,18163,10561,52959,69757,42855,56951,58747,99425,03036,64541,49396,31995,026101,317110,272105,12290,43473,12676,27982,93088,423103,743124,141132,986152,530172,669193,005192,493212,526231,840251,534252,853272,881274,212196,579209,569220,7548,3768,7509,98811,78310,10210,46112,5666,3936,2666,6226,9794,3333,3891,4721,5560000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
172,501
152,530
132,843
123,074
103,001
87,694
82,214
75,576
72,436
89,913
100,874
110,272
101,317
95,026
96,319
40,493
35,645
24,530
47,994
51,587
55,569
57,428
58,396
60,156
61,328
64,190
57,823
54,055
49,776
45,559
49,701
18,493
16,220
40,074
57,920
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000057,92040,07416,22018,49349,70145,55949,77654,05557,82364,19061,32860,15658,39657,42855,56951,58747,99424,53035,64540,49396,31995,026101,317110,272100,87489,91372,43675,57682,21487,694103,001123,074132,843152,530172,501000000000000000000000000000000
> Total Stockholder Equity
13,438
0
0
0
-26,707
-39,080
50,675
44,981
46,142
39,829
29,388
23,071
61,779
117,916
110,077
104,777
201,174
190,027
179,270
192,935
199,168
202,812
199,169
204,557
202,125
198,744
184,482
182,021
177,965
171,830
165,478
160,643
158,233
145,567
136,551
127,873
117,997
197,378
188,287
177,160
134,053
311,556
308,175
297,582
270,347
954,973
942,269
904,478
936,267
1,496,510
1,408,604
1,321,604
1,264,714
1,189,051
1,098,482
1,014,968
920,221
830,901
1,122,966
1,058,835
1,766,431
1,754,805
1,620,802
1,478,119
1,301,965
1,546,986
1,757,195
1,607,087
1,438,692
1,349,729
1,399,726
1,215,023
1,016,247
926,190
853,362
755,893
588,203
401,166
176,040
-67,638
-158,223
-259,240
-408,131
-165,866
-220,644
-219,272
-3,067
32,354
67,088
115,435
250,591
250,591115,43567,08832,354-3,067-219,272-220,644-165,866-408,131-259,240-158,223-67,638176,040401,166588,203755,893853,362926,1901,016,2471,215,0231,399,7261,349,7291,438,6921,607,0871,757,1951,546,9861,301,9651,478,1191,620,8021,754,8051,766,4311,058,8351,122,966830,901920,2211,014,9681,098,4821,189,0511,264,7141,321,6041,408,6041,496,510936,267904,478942,269954,973270,347297,582308,175311,556134,053177,160188,287197,378117,997127,873136,551145,567158,233160,643165,478171,830177,965182,021184,482198,744202,125204,557199,169202,812199,168192,935179,270190,027201,174104,777110,077117,91661,77923,07129,38839,82946,14244,98150,675-39,080-26,70700013,438
   Common Stock
0
0
0
0
0
0
200
201
208
209
209
212
267
320
321
322
371
375
376
406
408
408
411
414
414
414
417
418
418
419
421
422
423
424
427
427
427
519
520
524
525
621
624
632
637
755
763
767
772
842
845
847
851
855
856
858
859
861
917
924
997
1,005
1,005
1,009
1,011
1,064
1,110
1,113
1,122
1,131
1,156
1,161
1,164
1,173
1,186
1,195
1,202
1,207
1,210
1,230
1,240
1,243
1,250
1,255
1,259
1,265
1,281
1,289
1,293
1,303
1,310
1,3101,3031,2931,2891,2811,2651,2591,2551,2501,2431,2401,2301,2101,2071,2021,1951,1861,1731,1641,1611,1561,1311,1221,1131,1101,0641,0111,0091,0051,005997924917861859858856855851847845842772767763755637632624621525524520519427427427424423422421419418418417414414414411408408406376375371322321320267212209209208201200000000
   Retained Earnings Total Equity00000000-7,019,474-6,743,450-6,569,349-6,361,856-5,955,936-5,678,534-5,438,193-5,179,733-4,975,219-4,785,660-4,585,369-4,341,829-4,088,538-3,909,309-3,727,088-3,450,903-3,242,368-3,022,887-2,840,972-2,629,531-2,384,249-2,220,689-2,147,685-2,005,458-1,882,521-1,764,101-1,656,811-1,543,877-1,439,806-1,349,677-1,246,703-1,155,982-1,079,190-1,007,407-956,630-935,241-891,252-847,178-596,235-563,878-534,192-516,023-507,010-444,822-425,320-412,364-400,996-386,693-373,456-359,632-343,347-336,417-326,787000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-4,605
-7,672
-6,162
-4,318
-3,277
-2,934
-2,973
-2,889
-2,602
-1,682
-819
128
551
571
536
145
300
646
-1,660
-1,099
1,186
623
1,621
1,889
716
823
1,286
1,288
714
-18
-246
-151
-165
-37
-62
108
15,662
20,821
28,130
27,168
19,717
25,030
21,983
15,186
48,763
52,385
18,762
-7,219
4,369
-9,011
-28,296
-27,778
-33,441
-33,828
-33,959
-33,741
-34,433
-34,853
-33,807
-33,392
-33,213
-32,853
-35,831
-34,371
-36,518
-32,059
-33,212
-37,193
-43,622
-36,717
-36,081
-34,230
-33,259
-38,065
-42,224
-43,783
-44,654
-39,124
-37,080
-32,339
-23,375
-26,988
-34,637
-24,826
-34,518
-37,517
-29,952
-29,952-37,517-34,518-24,826-34,637-26,988-23,375-32,339-37,080-39,124-44,654-43,783-42,224-38,065-33,259-34,230-36,081-36,717-43,622-37,193-33,212-32,059-36,518-34,371-35,831-32,853-33,213-33,392-33,807-34,853-34,433-33,741-33,959-33,828-33,441-27,778-28,296-9,0114,369-7,21918,76252,38548,76315,18621,98325,03019,71727,16828,13020,82115,662108-62-37-165-151-246-187141,2881,2868237161,8891,6216231,186-1,099-1,660646300145536571551128-819-1,682-2,602-2,889-2,973-2,934-3,277-4,318-6,162-7,672-4,6050000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
490,558
495,350
500,443
504,793
509,826
514,290
518,731
609,260
613,149
621,350
624,876
806,137
813,613
833,660
846,228
1,776,366
1,810,775
1,823,766
1,843,362
2,450,690
2,468,187
2,483,958
2,506,197
2,546,884
2,565,728
2,585,765
2,609,614
2,627,969
3,038,529
3,097,110
3,947,552
4,009,342
4,037,853
4,140,033
4,175,139
4,601,662
5,034,284
5,091,248
5,201,176
5,289,966
5,520,320
5,592,884
5,644,074
5,747,394
5,863,476
5,968,661
6,058,453
6,116,558
6,172,990
6,336,771
6,454,540
6,522,091
6,647,173
0
0
0
0
0
0
0
0
000000006,647,1736,522,0916,454,5406,336,7716,172,9906,116,5586,058,4535,968,6615,863,4765,747,3945,644,0745,592,8845,520,3205,289,9665,201,1765,091,2485,034,2844,601,6624,175,1394,140,0334,037,8534,009,3423,947,5523,097,1103,038,5292,627,9692,609,6142,585,7652,565,7282,546,8842,506,1972,483,9582,468,1872,450,6901,843,3621,823,7661,810,7751,776,366846,228833,660813,613806,137624,876621,350613,149609,260518,731514,290509,826504,793500,443495,350490,558000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
7,416
12,525
107,526
106,403
112,216
112,158
112,902
117,176
170,033
234,057
235,264
236,416
340,779
351,252
353,221
420,039
424,453
428,990
440,410
448,092
452,767
457,838
465,277
471,755
476,663
482,743
490,558
495,350
500,443
504,793
509,826
514,290
518,731
609,260
613,149
621,350
624,876
806,137
813,613
833,660
846,228
1,776,366
1,810,775
1,823,766
1,843,362
2,450,690
2,468,187
2,483,958
2,506,197
2,546,884
2,565,728
2,585,765
2,609,614
2,627,969
3,038,529
3,097,110
3,947,552
4,009,342
4,037,853
4,140,033
4,175,139
4,601,662
5,034,284
5,091,248
5,201,176
5,289,966
5,520,320
5,592,884
5,644,074
5,747,394
5,863,476
5,968,661
6,058,453
6,116,558
6,172,990
6,336,771
6,454,540
6,522,091
6,647,173
6,736,939
6,811,063
6,881,977
7,122,704
7,259,876
7,388,061
7,496,876
7,690,737
7,690,7377,496,8767,388,0617,259,8767,122,7046,881,9776,811,0636,736,9396,647,1736,522,0916,454,5406,336,7716,172,9906,116,5586,058,4535,968,6615,863,4765,747,3945,644,0745,592,8845,520,3205,289,9665,201,1765,091,2485,034,2844,601,6624,175,1394,140,0334,037,8534,009,3423,947,5523,097,1103,038,5292,627,9692,609,6142,585,7652,565,7282,546,8842,506,1972,483,9582,468,1872,450,6901,843,3621,823,7661,810,7751,776,366846,228833,660813,613806,137624,876621,350613,149609,260518,731514,290509,826504,793500,443495,350490,558482,743476,663471,755465,277457,838452,767448,092440,410428,990424,453420,039353,221351,252340,779236,416235,264234,057170,033117,176112,902112,158112,216106,403107,52612,5257,4160000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,248,243
Cost of Revenue-323,370
Gross Profit1,924,8731,924,873
 
Operating Income (+$)
Gross Profit1,924,873
Operating Expense-2,101,758
Operating Income-176,885-176,885
 
Operating Expense (+$)
Research Development1,126,232
Selling General Administrative975,526
Selling And Marketing Expenses0
Operating Expense2,101,7582,101,758
 
Net Interest Income (+$)
Interest Income121,992
Interest Expense-141,858
Other Finance Cost-0
Net Interest Income-19,866
 
Pretax Income (+$)
Operating Income-176,885
Net Interest Income-19,866
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-377,37523,605
EBIT - interestExpense = -377,375
-377,375
-136,299
Interest Expense141,858
Earnings Before Interest and Taxes (EBIT)-235,517-235,517
Earnings Before Interest and Taxes (EBITDA)-178,847
 
After tax Income (+$)
Income Before Tax-377,375
Tax Provision--99,218
Net Income From Continuing Ops-278,157-278,157
Net Income-278,157
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,425,128
Total Other Income/Expenses Net-200,49019,866
 

Technical Analysis of Alnylam
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alnylam. The general trend of Alnylam is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alnylam's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Alnylam Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alnylam Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 484.21.

The bearish price targets are: 441.50 > 333.70 > 310.22.

Know someone who trades $ALNY? Share this with them.👇

Alnylam Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alnylam Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alnylam Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alnylam Pharmaceuticals Inc. The current macd is 15.14.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alnylam price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Alnylam. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Alnylam price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Alnylam Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAlnylam Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alnylam Pharmaceuticals Inc. The current adx is 51.21.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Alnylam shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Alnylam Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alnylam Pharmaceuticals Inc. The current sar is 445.60.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Alnylam Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alnylam Pharmaceuticals Inc. The current rsi is 61.44. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Alnylam Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAlnylam Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alnylam Pharmaceuticals Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alnylam price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Alnylam Pharmaceuticals Inc Daily Stochastic Oscillator ChartAlnylam Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alnylam Pharmaceuticals Inc. The current cci is 43.08.

Alnylam Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAlnylam Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alnylam Pharmaceuticals Inc. The current cmo is 12.28.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Alnylam Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAlnylam Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alnylam Pharmaceuticals Inc. The current willr is -53.78131585.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Alnylam is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Alnylam Pharmaceuticals Inc Daily Williams %R ChartAlnylam Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alnylam Pharmaceuticals Inc. The current atr is 12.82.

Alnylam Pharmaceuticals Inc Daily Average True Range (ATR) ChartAlnylam Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alnylam Pharmaceuticals Inc. The current obv is 34,720,363.

Alnylam Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAlnylam Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alnylam Pharmaceuticals Inc. The current mfi is 54.90.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Alnylam Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAlnylam Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alnylam Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-17MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-20MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-31ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Alnylam Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alnylam Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.440
Ma 20Greater thanMa 50457.484
Ma 50Greater thanMa 100404.491
Ma 100Greater thanMa 200348.558
OpenGreater thanClose465.210
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Alnylam with someone you think should read this too:
  • Are you bullish or bearish on Alnylam? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alnylam? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alnylam Pharmaceuticals Inc

I send you an email if I find something interesting about Alnylam Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Alnylam Pharmaceuticals Inc.

Receive notifications about Alnylam Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.